Results 111 to 120 of about 851,785 (340)

Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation [PDF]

, 2017
RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs).
Arora, Vivek K, Bolzenius, Jennifer, Bowman, Gregory R, Chu, Clarence E, Halstead, Angela M, Kapadia, Chiraag D, Schriefer, Andrew, Wartman, Lukas D   +7 more
core   +2 more sources

Author response for "Current standards and pitfalls associated with the transfection of primary fibroblast cells"

, 2021
Mirosław Kucharski, Patrycja Mrowiec, Ewa Ocłoń   +2 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Poly(2-oxazolines) in biological and biomedical application contexts. [PDF]

, 2007
Polyoxazolines of various architectures and chemical functionalities can be prepared in a living and therefore controlled manner via cationic ring-opening polymerisation.
Adams, Nico, Schubert, Ulrich S
core   +1 more source

682. Controlled Release of Peptide Moieties from Bioplex Transfection Complexes [PDF]

, 2002

openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Association between adeno‐associated virus genomic titers and intracellular plasmid levels

Engineering Reports
The recombinant adeno‐associated viral (rAAV) vector is one of the most effective viral vectors in gene therapy because of its low immunogenicity, high transduction efficiency, broad tissue specificity, and long‐term transgene expression ability. HEK293T
Kyoko Masumi‐Koizumi, Yuzhe Yuan, Kiyoko Higashiyama, Keisuke Yusa, Kazuhisa Uchida   +4 more
doaj   +1 more source

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia : implication for therapy [PDF]

, 2017
This work was supported by: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 x mille n.9980, (to M.F., F.M. A. N., P.T. and M.N.) ; AIRC I.G. n. 14326 (to M.F.), n.10136 and 16722 (A.N.), n.15426 (to F.F.).
Baio, G., Basso, L., Boccardo, S., Calabrese, M., Cilli, M., Colombo, M., Cutrona, G., Emionite, L., Fabris, S., Fais, F., Ferrarini, M., Gentile, M., Massara, R ., Massucco, C., Matis, S., Morabito, F., Negrini, M., Neri, A., Neumaier, C. E., Recchia, A. G., Reverberi, D., Rosa, F., Salvi, S., Tassone, P., Truini, M., Valdora, F., Zupo, S.   +26 more
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson’s Disease

Molecular Therapy: Nucleic Acids, 2017
RNA interference (RNAi)-based strategies that mediate the specific knockdown of target genes by administration of small interfering RNAs (siRNAs) could be applied for treatment of presently incurable neurodegenerative diseases such as Parkinson’s disease.
Christin Helmschrodt, Sabrina Höbel, Sandra Schöniger, Anne Bauer, Jana Bonicelli, Marieke Gringmuth, Simone A. Fietz, Achim Aigner, Angelika Richter, Franziska Richter   +9 more
doaj   +1 more source